Anthony Higham, SERB CEO
May 11, 2023 07:30 AM EDTUpdated 07:43 AM
Deals

Ex­clu­sive: Af­ter win­ning le­gal bat­tle, for­mer Phase­Bio in­vestor finds US buy­er for its PhI­II drug to re­verse Bril­in­ta

Amber Tong

Hav­ing wran­gled con­trol of a blood thin­ner re­ver­sal agent, SFJ Phar­ma has found a buy­er for the drug.

SERB Phar­ma­ceu­ti­cals, a spe­cial­ty phar­ma that vast­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times